Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24460225 | 0.83 | PIK3CG (0.44) | APPNPC1MAPTRAB9AKDM4E | |
| SCHEMBL24066056 | 0.80 | MCHR1 (0.33) | SCN10ANPC1MAPTRAB9AKDM4E | |
| SCHEMBL21033458 | 0.80 | ALDH1A3 (0.50) | APPKDM4EMCHR1 | |
| SCHEMBL22515692 | 0.77 | KLKB1 (0.34) | PIK3CA | |
| SCHEMBL21033467 | 0.76 | ALDH1A3 (0.49) | APPNPC1RAB9AKDM4E | |
| SCHEMBL14701750 | 0.75 | MCHR1 (0.41) | SCN10AAPPNPC1MAPTRAB9A | |
| Bromide SCHEMBL4471389 | 0.73 | MCHR1 (0.40) | SCN10AAPPNPC1RAB9AKDM4E | |
| SCHEMBL23950992 | 0.72 | PIK3CG (0.38) | SCN10AAPPNPC1RAB9AKDM4E | |
| SCHEMBL21033469 | 0.71 | ENPP2 (0.39) | PIK3CAMCHR1 | |
| SCHEMBL3545619 | 0.70 | KDM4E (0.64) | NPC1MAPTRAB9AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2021209552-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | SCN10A 3079/4885APP 147/4885NPC1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.